SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

BMO Capital Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to $142

BMO Capital maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $147 to $142.

Benzinga · 05/07/2020 17:18

BMO Capital maintains Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform and lowers the price target from $147 to $142.